Background: The development of chemotherapy of advanced intermediate- and high-
grade non-Hodgkin lymphoma provides more improved complete remission rate and
survival than the past, and now shows the increasing possibility of cure of the disease.
Methods : From March 1991 to February 1994, previously untreated 40 patients with
stage Ⅱ, Ⅲ, or Ⅳ intermediate- and high-grade non-Hodgkin lymphoma were treated
with ProMACE-CytaBOM regimen including prednisone, cyclophosphamide, doxorubicin,
etoposide, cytarabine, bleomycin, vincristine, methotrexate, and leucovorin. Medical
records were reviewed and analysis was done with 40 cases.
Results : Twenty one patients(53%) achieved complete remission(CR) and 12 patients
(30%) had partial remission. Four out of 21 complete responders relapsed. The duration
of complete remission was 7+-33+ months and the duration
of survival was 2-33+ months. Two year relapse free survival rate was
72% and the 2 year overall survival rate was 53%. The most frequent hematologic
toxicity was leukopenia(16%). The most common non-hematologic toxicity was
alopecia(85%), and nausea and vomiting(63%). Two patients died during
chemotherapy(one patient due to sepsis and one with tumor lysis syndrome and sepsis).
Conclusion: The ProMACE-CytaBOM combination chemotherapy is relatively safe
and effective treatment for patients with advanced intermediate-and high-grade
non-Hodgkin lymphoma. Further evaluation for prognostic factors will be necessary.

Keywords: Non-Hodgkin lymphoma, ProMACE-CytaBOM chemotherapy, Remission rate, Survival rate, Prognostic factor, Toxicity